The challenges of integrating molecular imaging into the optimization of cancer therapy

Integrative Biology

Volumn 3, Issue 6, 2011, Pages 603-631

  Patel, G S ^a   Kiuchi, T ^a   Lawler, K ^a   Ofo, E ^a,b   Fruhwirth, G O ^a   Kelleher, M ^a,c   Shamil, E ^a   Zhang, R ^d   Selvin, P R ^d   Santis, G ^e   Spicer, J ^a   Woodman, N ^e   Gillett, C E ^a,e   Barber, P R ^f   Vojnovic, B ^f,g   Keri G ^h,i   Schaeffter, T ^a   Goh, V ^a   O'Doherty, M J ^j   Ellis, P A ^a   Ng, T ^a   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d University of Illinois at Urbana Champaign   (United States)

^e GUY S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h Vichem Chemie Research Ltd   (Hungary)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j ST THOMAS HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ACETIC ACID; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CARBON 11; CISPLATIN; COPPER 64; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; FLUORINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GALLIUM 68; IMATINIB; IODINE 124; LIPOCORTIN 5; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN; VITRONECTIN RECEPTOR; ZIRCONIUM 89; ZIRCONIUM DERIVATIVE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BLOOD OXYGENATION; BRAIN CANCER; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CANCER TISSUE; CELL DEATH; CELL PROLIFERATION; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DIGITAL MAMMOGRAPHY; DOSIMETRY; DRUG DISTRIBUTION; DRUG MONITORING; DRUG RESPONSE; ENDOSCOPIC BIOPSY; ESOPHAGUS CANCER; FLUORESCENCE IMAGING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAMMOGRAPHY; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTICAL COHERENCE TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION EXPOSURE; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID CANCER; TUMOR CELL; TUMOR GENE; TUMOR XENOGRAFT; X RAY;

HUMANS; MOLECULAR IMAGING; NEOPLASM PROTEINS; NEOPLASMS; SYSTEMS INTEGRATION; TUMOR MARKERS, BIOLOGICAL;

EID: 79959199867     PISSN: 17579694     EISSN: 17579708     Source Type: Journal    
DOI: 10.1039/c0ib00131g     Document Type: Review

References (286)

1. J. A. DiMasi, R. W. Hansen and H. G. Grabowski, The price of innovation: new estimates of drug development costs, J. Health Econ., 2003, 22, 151-85, DOI: 10.1016/S0167-6296(02)00126-1.
2. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Y. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. P. Dong and J. Baselga, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected], J. Clin. Oncol., 2003, 21, 2237-46;
3. E. E. Cohen, F. Rosen, W. M. Stadler, W. Recant, K. Stenson, D. Huo and E. E. Vokes, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck, J. Clin. Oncol., 2003, 21, 1980-7;
4. L. B. Saltz, N. J. Meropol, P. J. Loehrer, Sr., M. N. Needle, J. Kopit and R. J. Mayer, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J. Clin. Oncol., 2004, 22, 1201-8;
5. R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabarbara and P. Bonomi, Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer, J. Clin. Oncol., 2004, 22, 3238-47. (Pubitemid 41103678)
6. L. Toschi and F. Cappuzzo, Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors, Oncologist, 2007, 12, 211-20, DOI: 10.1634/theoncologist.12-2-211.
7. F. Cappuzzo, V. Gregorc, E. Rossi, A. Cancellieri, E. Magrini, C. T. Paties, G. Ceresoli, L. Lombardo, S. Bartolini, C. Calandri, M. de Rosa, E. Villa and L. Crino, Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC, J. Clin. Oncol., 2003, 21, 2658-63, DOI: 10.1200/JCO.2003.01.039; (Pubitemid 46606308)
8. H. S. Parra, R. Cavina, F. Latteri, P. A. Zucali, E. Campagnoli, E. Morenghi, G. C. Grimaldi, M. Roncalli and A. Santoro, Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer, Br. J. Cancer, 2004, 91, 208-12, DOI: 10.1038/sj.bjc.6601923. (Pubitemid 39037060)
9. J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson and M. Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 2004, 304, 1497-500, DOI: 10.1126/science.1099314; (Pubitemid 38720929)
10. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman and D. A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 2004, 350, 2129-39, DOI: 10.1056/NEJMoa040938.
11. Z. Chen, J. Feng, J. S. Saldivar, D. Gu, A. Bockholt and S. S. Sommer, EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids, Oncogene, 2008, 27, 4336-43, DOI: 10.1038/onc.2008.71.
12. A. Hochhaus, S. Kreil, A. S. Corbin, P. La Rosee, M. C. Muller, T. Lahaye, B. Hanfstein, C. Schoch, N. C. Cross, U. Berger, H. Gschaidmeier, B. J. Druker and R. Hehlmann, Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy, Leukemia, 2002, 16, 2190-6, DOI: 10.1038/sj.leu. 2402741. (Pubitemid 35331833)
13. M. W. Teng, J. B. Swann, C. M. Koebel, R. D. Schreiber and M. J. Smyth, Immune-mediated dormancy: an equilibrium with cancer, J. Leukocyte Biol., 2008, 84, 988-93, DOI: 10.1189/jlb.1107774.
14. L. Fass, Imaging and cancer: a review, Mol. Oncol., 2008, 2, 115-52, DOI: 10.1016/j.molonc.2008.04.001.
15. J. K. Willmann, N. van Bruggen, L. M. Dinkelborg and S. S. Gambhir, Molecular imaging in drug development, Nat. Rev. Drug Discovery, 2008, 7, 591-607, DOI: 10.1038/nrd2290.
16. K. H. Bohuslavizki, Somatostatin receptor imaging: current status and future perspectives, J. Nucl. Med., 2001, 42, 1057-8.
17. 68Gallium-DOTA-peptides in NET: An overview, Eur. J. Radiol., 2010, DOI: 10.1016/j.ejrad.2010.07.022.
18. D. J. Kwekkeboom, B. L. Kam, M. van Essen, J. J. Teunissen, C. H. van Eijck, R. Valkema, M. de Jong, W. W. de Herder and E. P. Krenning, Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors, Endocr. Relat. Cancer, 2009, 17, R53-73, DOI: 10.1677/ERC-09-0078.
19. 18F]FDG PET in clinical oncology, Lancet Oncol., 2007, 8, 822-30, DOI: 10.1016/S1470-2045(07)70274-7.
20. G. Bertolini, L. Roz, P. Perego, M. Tortoreto, E. Fontanella, L. Gatti, G. Pratesi, A. Fabbri, F. Andriani, S. Tinelli, E. Roz, R. Caserini, S. Lo Vullo, T. Camerini, L. Mariani, D. Delia, E. Calabro, U. Pastorino and G. Sozzi, Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment, Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 16281-6, DOI: 10.1073/pnas.0905653106.
21. 64Cu]AMD3100 positron emission tomography, Cancer Res., 2010, 70, 3935-44, DOI: 10.1158/0008-5472.CAN-09-4396.
22. T. F. Massoud and S. S. Gambhir, Molecular imaging in living subjects: seeing fundamental biological processes in a new light, Genes Dev., 2003, 17, 545-80, DOI: 10.1101/gad.1047403.
23. U. Wilking, E. Karlsson, L. Skoog, T. Hatschek, E. Lidbrink, G. Elmberger, H. Johansson, L. Lindstrom and J. Bergh, HER2 status in a population-derived breast cancer cohort: discordances during tumor progression, Breast Cancer Res. Treat., 2010, 125, 553, DOI: 10.1007/s10549-010-1029-2.
24. C. Sotiriou and L. Pusztai, Gene-expression signatures in breast cancer, N. Engl. J. Med., 2009, 360, 790-800, DOI: 10.1056/NEJMra0801289.
25. D. C. Allred, Y. Wu, S. Mao, I. D. Nagtegaal, S. Lee, C. M. Perou, S. K. Mohsin, P. O'Connell, A. Tsimelzon and D. Medina, Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution, Clin. Cancer Res., 2008, 14, 370-8, DOI: 10.1158/1078-0432.CCR-07-1127; (Pubitemid 351226103)
26. W. J. Lennington, R. A. Jensen, L. W. Dalton and D. L. Page, Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions, Cancer, 1994, 73, 118-24.
27. X. Chen, K. L. Reichenbach and C. Xu, Experimental and theoretical analysis of core-to-core coupling on fiber bundle imaging, Opt. Express, 2008, 16, 21598-607, DOI: 10.1364/OE.16.021598;
28. H. Inoue, S. E. Kudo and A. Shiokawa, Technology insight: Laser-scanning confocal microscopy and endocytoscopy for cellular observation of the gastrointestinal tract, Nat. Clin. Pract. Gastroenterol. Hepatol., 2005, 2, 31-7, DOI: 10.1038/ncpgasthep0072. (Pubitemid 40812525)
29. J. Baselga and S. M. Swain, Novel anticancer targets: revisiting ERBB2 and discovering ERBB3, Nat. Rev. Cancer, 2009, 9, 463-75, DOI: 10.1038/nrc2656.
30. H. Fan-Minogue, Z. Cao, R. Paulmurugan, C. T. Chan, T. F. Massoud, D. W. Felsher and S. S. Gambhir, Noninvasive molecular imaging of c-Myc activation in living mice, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 15892, DOI: 10.1073/pnas.1007443107;
31. A. De, P. Ray, A. M. Loening and S. S. Gambhir, BRET3: a red-shifted bioluminescence resonance energy transfer (BRET)-based integrated platform for imaging protein-protein interactions from single live cells and living animals, FASEB J., 2009, 23, 2702-9, DOI: 10.1096/fj.08-118919.
32. T. F. Massoud, R. Paulmurugan and S. S. Gambhir, A molecularly engineered split reporter for imaging protein-protein interactions with positron emission tomography, Nat. Med., 2010, 16, 921-6, DOI: 10.1038/nm.2185.
33. G. Tarcic, S. K. Boguslavsky, J. Wakim, T. Kiuchi, A. Liu, F. Reinitz, D. Nathanson, T. Takahashi, P. S. Mischel, T. Ng and Y. Yarden, An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis, Curr. Biol., 2009, 19, 1788-98;
34. M. Parsons, J. Monypenny, S. M. Ameer-Beg, T. H. Millard, L. M. Machesky, M. Peter, M. D. Keppler, G. Schiavo, R. Watson, J. Chernoff, D. Zicha, B. Vojnovic and T. Ng, Spatially distinct binding of Cdc42 to PAK1 and N-WASP in breast carcinoma cells, Mol. Cell. Biol., 2005, 25, 1680-95, DOI: 10.1128/MCB.25.5.1680-1695.2005; (Pubitemid 40280137)
35. R. F. Carvalho, M. Beutler, K. J. Marler, B. Knoll, E. Becker-Barroso, R. Heintzmann, T. Ng and U. Drescher, Silencing of EphA3 through a cis interaction with ephrinA5, Nat. Neurosci., 2006, 9, 322-30;
36. D. Romano, D. Matallanas, G. Weitsman, C. Preisinger, T. Ng and W. Kolch, Proapoptotic Kinase MST2 Coordinates Signaling Crosstalk between RASSF1A, Raf-1, and Akt, Cancer Res., 2010, 70, 1195-203;
37. T. Ng, D. Shima, A. Squire, P. I. Bastiaens, S. Gschmeissner, M. J. Humphries and P. J. Parker, PKCalpha regulates beta1 integrin-dependent cell motility through association and control of integrin traffic, EMBO J., 1999, 18, 3909-23, DOI: 10.1093/emboj/18.14.3909;
38. T. Niault, I. Sobczak, K. Meissl, G. E. Weitsman, D. Piazzolla, K. Ehrenreiter, M. Hamerl, I. Moarefi, T. Leung, O. Carugo, T. Ng and M. Baccarini, From Autoinhibition to Inhibition in Trans: the Raf-1 Regulatory Domain Inhibits Rok-a Kinase Activity, J. Cell Biol., 2009, 187, 335-342;
39. N. Anilkumar, M. Parsons, R. Monk, T. Ng and J. C. Adams, Interaction of fascin and protein kinase Calpha: a novel intersection in cell adhesion and motility, EMBO J., 2003, 22, 5390-402, DOI: 10.1093/emboj/cdg521;
40. K. Makrogianneli, L. M. Carlin, M. D. Keppler, D. R. Matthews, E. Ofo, A. Coolen, S. M. Ameer-Beg, P. R. Barber, B. Vojnovic and T. Ng, Integrating receptor signal inputs that influence small Rho GTPase activation dynamics at the immunological synapse, Mol. Cell. Biol., 2009, 29, 2997-3006;
41. L. M. Carlin, K. Makrogianneli, M. Keppler, G. O. Fruhwirth and T. Ng, Visualisation of signalling in immune cells, Methods Mol. Biol., 2010, 616, 97-113, DOI: 10.1007/978-1-60761-461-6-7;
42. D. R. Matthews, L. M. Carlin, E. Ofo, P. R. Barber, B. Vojnovic, M. Irving, T. Ng and S. M. Ameer-Beg, Time-lapse FRET microscopy using fluorescence anisotropy, J. Microsc., 2010, 237, 51-62, DOI: 10.1111/j.1365-2818.2009.03301. x;
43. M. Beutler, K. Makrogianneli, R. J. Vermeij, M. Keppler, T. Ng, T. M. Jovin and R. Heintzmann, satFRET: estimation of Forster resonance energy transfer by acceptor saturation, Eur. Biophys. J., 2008, 38, 69-82, DOI: 10.1007/s00249-008-0361-5;
44. S. J. Heasman, L. M. Carlin, S. Cox, T. Ng and A. J. Ridley, Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration, J. Cell Biol., 2010, 190, 553-63, DOI: 10.1083/jcb.201002067.
45. E. M. Bublil, G. Pines, G. Patel, G. Fruhwirth, T. Ng and Y. Yarden, Kinase-mediated quasi-dimers of EGFR, FASEB J., 2010, 24, 4744, DOI: 10.1096/fj.10-166199.
46. T. Ng, M. Parsons, W. E. Hughes, J. Monypenny, D. Zicha, A. Gautreau, M. Arpin, S. Gschmeissner, P. J. Verveer, P. I. Bastiaens and P. J. Parker, Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility, EMBO J., 2001, 20, 2723-41, DOI: 10.1093/emboj/20.11. 2723;
47. J. W. Legg, C. A. Lewis, M. Parsons, T. Ng and C. M. Isacke, A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility, Nat. Cell Biol., 2002, 4, 399-407, DOI: 10.1038/ncb797. (Pubitemid 34746157)
48. M. T. Kelleher, G. Fruhwirth, G. Patel, E. Ofo, F. Festy, P. R. Barber, S. M. Ameer-Beg, B. Vojnovic, C. Gillett, A. Coolen, G. Keri, P. A. Ellis and T. Ng, The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients, Targeted Oncol., 2009, 4, 235-52, DOI: 10.1007/s11523-009-0116-y.
49. T. Ng, A. Squire, G. Hansra, F. Bornancin, C. Prevostel, A. Hanby, W. Harris, D. Barnes, S. Schmidt, H. Mellor, P. I. Bastiaens and P. J. Parker, Imaging protein kinase Calpha activation in cells, Science, 1999, 283, 2085-9.
50. H. J. Choi, W. Ju, S. K. Myung and Y. Kim, Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis, Cancer Sci., 2010, 101, 1471-9, DOI: 10.1111/j.1349-7006. 2010.01532.x;
51. T. C. Kwee and R. M. Kwee, Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis, Eur. Radiol., 2009, 19, 731-44, DOI: 10.1007/s00330-008-1194-4.
52. L. Pan, P. Gu, G. Huang, H. Xue and S. Wu, Prognostic significance of SUV on PET/CT in patientswith esophageal cancer: a systematic review and meta-analysis, Eur. J. Gastroenterol. Hepatol., 2009, 21, 1008-15, DOI: 10.1097/MEG.0b013e328323d6fa;
53. 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis, J. Nucl. Med., 2010, 51, 1507-16, DOI: 10.2967/jnumed.110.075457;
54. L. S. Poulou, L. Thanos and P. D. Ziakas, Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials, Eur. J. Nucl. Med. Mol. Imaging, 2009, 37, 156-62, DOI: 10.1007/s00259-009-1258-y.
55. M. Paesmans, T. Berghmans, M. Dusart, C. Garcia, C. Hossein-Foucher, J. J. Lafitte, C. Mascaux, A. P. Meert, M. Roelandts, A. Scherpereel, V. Terrones Munoz and J. P. Sculier, Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project, J. Thorac. Oncol., 2010, 5, 612-9, DOI: 10.1097/JTO.0b013e3181d0a4f5.
56. I. Astsaturov, V. Ratushny, A. Sukhanova, M. B. Einarson, T. Bagnyukova, Y. Zhou, K. Devarajan, J. S. Silverman, N. Tikhmyanova, N. Skobeleva, A. Pecherskaya, R. E. Nasto, C. Sharma, S. A. Jablonski, I. G. Serebriiskii, L. M. Weiner and E. A. Golemis, Synthetic lethal screen of an EGFR-centered network to improve targeted therapies, Sci. Signaling, 2010, 3, ra67, DOI: 10.1126/scisignal.2001083.
57. W. A. Weber, Use of PET for monitoring cancer therapy and for predicting outcome, J. Nucl. Med., 2005, 46, 983-95.
58. R. Boellaard, M. J. O'Doherty, W. A. Weber, F. M. Mottaghy, M. N. Lonsdale, S. G. Stroobants, W. J. Oyen, J. Kotzerke, O. S. Hoekstra, J. Pruim, P. K. Marsden, K. Tatsch, C. J. Hoekstra, E. P. Visser, B. Arends, F. J. Verzijlbergen, J. M. Zijlstra, E. F. Comans, A. A. Lammertsma, A. M. Paans, A. T. Willemsen, T. Beyer, A. Bockisch, C. Schaefer-Prokop, D. Delbeke, R. P. Baum, A. Chiti and B. J. Krause, FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0, Eur. J. Nucl. Med. Mol. Imaging, 2009, 37, 181-200, DOI: 10.1007/s00259-009-1297-4.
59. A. Szafer, J. Zhong, A. W. Anderson and J. C. Gore, Diffusionweighted imaging in tissues: theoretical models, NMR Biomed., 1995, 8, 289-96;
60. C. H. Sotak, Nuclear magnetic resonance (NMR) measurement of the apparent diffusion coefficient (ADC) of tissue water and its relationship to cell volume changes in pathological states, Neurochem. Int., 2004, 45, 569-82, DOI: 10.1016/j.neuint.2003.11.010;
61. A. R. Padhani, G. Liu, D. M. Koh, T. L. Chenevert, H. C. Thoeny, T. Takahara, A. Dzik-Jurasz, B. D. Ross, M. Van Cauteren, D. Collins, D. A. Hammoud, G. J. Rustin, B. Taouli and P. L. Choyke, Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations, Neoplasia, 2009, 11, 102-25.
62. R. G. Kierkels, W. H. Backes, M. H. Janssen, J. Buijsen, R. G. Beets-Tan, P. Lambin, G. Lammering, M. C. Oellers and H. J. Aerts, Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in rectal cancer, Int. J. Radiat. Oncol., Biol., Phys., 2010, 77, 400-8, DOI: 10.1016/j.ijrobp.2009.05.015;
63. V. Goh, M. Dattani, J. Farwell, J. Shekhdar, E. Tam, S. Patel, J. Juttla, I. Simcock, J. Stirling, H. Mandeville, E. Aird and P. Hoskin, Radiation dose from volumetric helical perfusion CT of the thorax, abdomen or pelvis, Eur. Radiol., 2010, 21, 974, DOI: 10.1007/s00330-010-1997-y.
64. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy, J. Nucl. Med., 2005, 46, 253-60.
65. H. Schoder and M. Gonen, Screening for cancer with PET and PET/CT: potential and limitations, J. Nucl. Med., Suppl., 2007, 48(Suppl 1), 4S-18S.
66. M. E. Juweid and B. D. Cheson, Positron-emission tomography and assessment of cancer therapy, N. Engl. J. Med., 2006, 354, 496-507, DOI: 10.1056/NEJMra050276;
67. P. Seam, M. E. Juweid and B. D. Cheson, The role of FDG-PET scans in patients with lymphoma, Blood, 2007, 110, 3507-16, DOI: 10.1182/blood-2007-06- 097238.
68. R. J. Downey, T. Akhurst, M. Gonen, A. Vincent, M. S. Bains, S. Larson and V. Rusch, Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection, J. Clin. Oncol., 2004, 22, 3255-60, DOI: 10.1200/JCO.2004.11.109. (Pubitemid 41103680)
69. K. A. Miles, Functional CT imaging in oncology, Eur. J. Radiol., 2003, 13(Suppl 5), M134-8.
70. Q. S. Ng, V. Goh, H. Fichte, E. Klotz, P. Fernie, M. I. Saunders, P. J. Hoskin and A. R. Padhani, Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements, Radiology, 2006, 239, 547-53, DOI: 10.1148/radiol.2392050568.
71. J. Yee, G. A. Akerkar, R. K. Hung, A. M. Steinauer-Gebauer, S. D. Wall and K. R. McQuaid, Colorectal neoplasia: performance characteristics of CT colonography for detection in 300 patients, Radiology, 2001, 219, 685-92.
72. E. D. Pisano, C. Gatsonis, E. Hendrick, M. Yaffe, J. K. Baum, S. Acharyya, E. F. Conant, L. L. Fajardo, L. Bassett, C. D'Orsi, R. Jong and M. Rebner, Diagnostic performance of digital versus film mammography for breast-cancer screening, N. Engl. J. Med., 2005, 353, 1773-83, DOI: 10.1056/NEJMoa052911. (Pubitemid 41549889)
73. C. H. Holdsworth, R. D. Badawi, J. B. Manola, M. F. Kijewski, D. A. Israel, G. D. Demetri and A. D. Van den Abbeele, CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor, AJR, Am. J. Roentgenol., 2007, 189, W324-30, DOI: 10.2214/AJR.07.2496;
74. C. Y. Wong, J. Schmidt, J. S. Bong, S. Chundru, L. Kestin, D. Yan, I. Grills, M. Gaskill, V. Cheng, A. A. Martinez and D. Fink-Bennett, Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET-CT imaging, Radiat. Oncol., 2007, 2, 18, DOI: 10.1186/1748-717X-2-18;
75. H. Kato, M. Fukuchi, T. Miyazaki, M. Nakajima, N. Tanaka, T. Inose, H. Kimura, A. Faried, K. Saito, M. Sohda, Y. Fukai, N. Masuda, R. Manda, H. Ojima, K. Tsukada, N. Oriuchi, K. Endo, T. Nonaka, M. Shioya, H. Ishikawa, H. Sakurai, T. Nakano and H. Kuwano, Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography, Anticancer Res., 2007, 27, 2627-33. (Pubitemid 47227975)
76. 18F-FDG PET in patients with non-small cell lung cancer, J. Nucl. Med., 2007, 48, 1592-8, DOI: 10.2967/jnumed.107.043414.
77. L. F. de Geus-Oei, H. W. van Laarhoven, E. P. Visser, R. Hermsen, B. A. van Hoorn, Y. J. Kamm, P. F. Krabbe, F. H. Corstens, C. J. Punt and W. J. Oyen, Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer, Ann. Oncol., 2008, 19, 348-52, DOI: 10.1093/annonc/mdm470. (Pubitemid 351201718)
78. N. Rizk, R. J. Downey, T. Akhurst, M. Gonen, M. S. Bains, S. Larson and V. Rusch, Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection, Ann. Thorac. Surg., 2006, 81, 1076-81, DOI: 10.1016/j.athoracsur. 2005.09.063; (Pubitemid 43247692)
79. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning, J. Clin. Endocrinol. Metab., 2006, 91, 498-505, DOI: 10.1210/jc.2005-1534.
80. S. C. Huang, Anatomy of SUV. Standardized uptake value, Nucl. Med. Biol., 2000, 27, 643-6, DOI: 10.1016/S0969-8051(00)00155-4.
81. W. A. Berg, I. N. Weinberg, D. Narayanan, M. E. Lobrano, E. Ross, L. Amodei, L. Tafra, L. P. Adler, J. Uddo, W. Stein, 3rd and E. A. Levine, High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer, Breast J., 2006, 12, 309-23, DOI: 10.1111/j.1075-122X. 2006.00269.x.
82. 18F]FAZA PET in head and neck cancer patients: a pilot study, Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1566-75, DOI: 10.1007/s00259-007-0424-3.
83. 18F]fluorothymidine positron emission tomography, Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1339-47, DOI: 10.1007/s00259-007-0379-4;
84. 18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors, Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, 412-9, DOI: 10.1007/s00259-005-0011-4.
85. K. J. Yagle, J. F. Eary, J. F. Tait, J. R. Grierson, J. M. Link, B. Lewellen, D. F. Gibson and K. A. Krohn, Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis, J. Nucl. Med., 2005, 46, 658-66. (Pubitemid 41716411)
86. H. M. Linden, S. A. Stekhova, J. M. Link, J. R. Gralow, R. B. Livingston, G. K. Ellis, P. H. Petra, L. M. Peterson, E. K. Schubert, L. K. Dunnwald, K. A. Krohn and D. A. Mankoff, Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer, J. Clin. Oncol., 2006, 24, 2793-9, DOI: 10.1200/JCO.2005.04.3810. (Pubitemid 46630578)
87. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses, J. Nucl. Med., 2003, 44, 213-21;
88. T. Ohtani, H. Kurihara, S. Ishiuchi, N. Saito, N. Oriuchi, T. Inoue and T. Sasaki, Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging, Eur. J. Nucl. Med. Mol. Imaging, 2001, 28, 1664-70, DOI: 10.1007/s002590100620. (Pubitemid 33036109)
89. M. K. Robinson, M. Doss, C. Shaller, D. Narayanan, J. D. Marks, L. P. Adler, D. E. Gonzalez Trotter and G. P. Adams, Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody, Cancer Res., 2005, 65, 1471-8, DOI: 10.1158/0008-5472.CAN-04-2008.
90. 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients, J. Nucl. Med., 2009, 50, 1828-36, DOI: 10.2967/jnumed.109.065862.
91. 18F-FRGD2, J. Nucl. Med., 2006, 47, 113-21.
92. P. M. Smith-Jones, D. B. Solit, T. Akhurst, F. Afroze, N. Rosen and S. M. Larson, Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors, Nat. Biotechnol., 2004, 22, 701-6, DOI: 10.1038/nbt968; (Pubitemid 38702826)
93. D. B. Solit, S. P. Ivy, C. Kopil, R. Sikorski, M. J. Morris, S. F. Slovin, W. K. Kelly, A. DeLaCruz, T. Curley, G. Heller, S. Larson, L. Schwartz, M. J. Egorin, N. Rosen and H. I. Scher, Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer, Clin. Cancer Res., 2007, 13, 1775-82, DOI: 10.1158/1078-0432.CCR-06-1863; (Pubitemid 46952945)
94. 18F-FDG PET, J. Nucl. Med., 2006, 47, 793-6.
95. M. V. Backer, Z. Levashova, V. Patel, B. T. Jehning, K. Claffey, F. G. Blankenberg and J. M. Backer, Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes, Nat. Med., 2007, 13, 504-9, DOI: 10.1038/nm1522. (Pubitemid 46559824)
96. 18F-paclitaxel in nonhuman primates, J. Nucl. Med., 2003, 44, 1330-9;
97. 18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study, Cancer Biother. Radiopharm., 1996, 11, 235-45;
98. M. Moehler, A. Dimitrakopoulou-Strauss, F. Gutzler, U. Raeth, L. G. Strauss and W. Stremmel, 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil, Cancer, 1998, 83, 245-53, DOI: 10.1002/(SICI)1097- 0142(19980715)83:2〈245::AID-CNCR7〉3.0.CO;2-P; (Pubitemid 28317803)
99. 13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors, J. Nucl. Med., 1987, 28, 1844-52.
100. S. M. Larson and H. Schoder, New PET tracers for evaluation of solid tumor response to therapy, Q. J. Nucl. Med. Mol. Imaging, 2009, 53, 158-66.
101. M. Bhattacharyya, D. Ryan, R. Carpenter, S. Vinnicombe and C. J. Gallagher, Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer, Br. J. Cancer, 2008, 98, 289-93, DOI: 10.1038/sj.bjc.6604171. (Pubitemid 351161258)
102. E. Warner, H. Messersmith, P. Causer, A. Eisen, R. Shumak and D. Plewes, Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer, Ann. Intern. Med., 2008, 148, 671-9;
103. M. O. Leach, MRI for breast cancer screening, Ann. Oncol., 2006, 17(Suppl 10), x325-31, DOI: 10.1093/annonc/mdl281.
104. A. R. Padhani, C. Hayes, L. Assersohn, T. Powles, A. Makris, J. Suckling, M. O. Leach and J. E. Husband, Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results, Radiology, 2006, 239, 361-74, DOI: 10.1148/radiol.2392021099.
105. M. L. George, A. S. Dzik-Jurasz, A. R. Padhani, G. Brown, D. M. Tait, S. A. Eccles and R. I. Swift, Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer, Br. J. Surg., 2001, 88, 1628-36, DOI: 10.1046/j.0007-1323.2001.01947.x. (Pubitemid 33124241)
106. M. O. Leach, K. M. Brindle, J. L. Evelhoch, J. R. Griffiths, M. R. Horsman, A. Jackson, G. C. Jayson, I. R. Judson, M. V. Knopp, R. J. Maxwell, D. McIntyre, A. R. Padhani, P. Price, R. Rathbone, G. J. Rustin, P. S. Tofts, G. M. Tozer, W. Vennart, J. C. Waterton, S. R. Williams and P. Workman, The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations, Br. J. Cancer, 2005, 92, 1599-610, DOI: 10.1038/sj.bjc.6602550. (Pubitemid 40756468)
107. K. M. Brindle, Molecular imaging using magnetic resonance: new tools for the development of tumour therapy, Br. J. Radiol., 2003, 76(Spec. No. 2), S111-7;
108. P. M. Winter, S. D. Caruthers, A. Kassner, T. D. Harris, L. K. Chinen, J. S. Allen, E. K. Lacy, H. Zhang, J. D. Robertson, S. A. Wickline and G. M. Lanza, Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel α(ν)b3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging, Cancer Res., 2003, 63, 5838-43.
109. P. M. Winter, A. H. Schmieder, S. D. Caruthers, J. L. Keene, H. Zhang, S. A. Wickline and G. M. Lanza, Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits, FASEB J., 2008, 22, 2758-67, DOI: 10.1096/fj.07-103929.
110. T. W. Stadnik, H. Everaert, S. Makkat, R. Sacre, J. Lamote and C. Bourgain, Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging-initial findings, Eur. Radiol., 2006, 16, 2153-60, DOI: 10.1007/s00330-006-0276-4. (Pubitemid 44354549)
111. W. M. Deserno, M. G. Harisinghani, M. Taupitz, G. J. Jager, J. A. Witjes, P. F. Mulders, C. A. Hulsbergen van de Kaa, D. Kaufmann and J. O. Barentsz, Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging, Radiology, 2004, 233, 449-56, DOI: 10.1148/radiol.2332031111;
112. M. G. Harisinghani, J. Barentsz, P. F. Hahn, W. M. Deserno, S. Tabatabaei, C. H. van de Kaa, J. de la Rosette and R. Weissleder, Noninvasive detection of clinically occult lymph-node metastases in prostate cancer, N. Engl. J. Med., 2003, 348, 2491-9, DOI: 10.1056/NEJMoa022749. (Pubitemid 36706536)
113. M. Zhao, D. A. Beauregard, L. Loizou, B. Davletov and K. M. Brindle, Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent, Nat. Med., 2001, 7, 1241-4, DOI: 10.1038/nm1101-1241. (Pubitemid 33063780)
114. D. Artemov, N. Mori, B. Okollie and Z. M. Bhujwalla, MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles, Magn. Reson. Med., 2003, 49, 403-8, DOI: 10.1002/mrm.10406.
115. W. J. Rogers, C. H. Meyer and C. M. Kramer, Technology insight: in vivo cell tracking by use of MRI, Nat. Clin. Pract. Cardiovasc. Med., 2006, 3, 554-62, DOI: 10.1038/ncpcardio0659.
116. E. A. Schellenberger, D. Hogemann, L. Josephson and R. Weissleder, Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI, Acad. Radiol., 2002, 9(Suppl 2), S310-1.
117. D. Le Bihan, C. Poupon, A. Amadon and F. Lethimonnier, Artifacts and pitfalls in diffusion MRI, J. Magn. Reson. Imaging, 2006, 24, 478-88, DOI: 10.1002/jmri.20683. (Pubitemid 44320549)
118. D. A. Hamstra, T. L. Chenevert, B. A. Moffat, T. D. Johnson, C. R. Meyer, S. K. Mukherji, D. J. Quint, S. S. Gebarski, X. Fan, C. I. Tsien, T. S. Lawrence, L. Junck, A. Rehemtulla and B. D. Ross, Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma, Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 16759-64, DOI: 10.1073/pnas.0508347102.
119. M. D. Pickles, P. Gibbs, M. Lowry and L. W. Turnbull, Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer, Magn. Reson. Imaging, 2006, 24, 843-7, DOI: 10.1016/j.mri.2005.11.005.
120. E. J. Vlieger, C. B. Majoie, S. Leenstra and G. J. Den Heeten, Functional magnetic resonance imaging for neurosurgical planning in neurooncology, Eur. Radiol., 2004, 14, 1143-53, DOI: 10.1007/s00330-004-2328-y. (Pubitemid 38979206)
121. S. P. Li, N. J. Taylor, A. Makris, M. L. Ah-See, M. J. Beresford, J. J. Stirling, J. A. d'Arcy, D. J. Collins and A. R. Padhani, Primary Human Breast Adenocarcinoma: Imaging and Histologic Correlates of Intrinsic Susceptibility-weighted MR Imaging before and during Chemotherapy, Radiology, 2010, 257, 643, DOI: 10.1148/radiol.10100421.
122. J. Oh, R. G. Henry, A. Pirzkall, Y. Lu, X. Li, I. Catalaa, S. Chang, W. P. Dillon and S. J. Nelson, Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume, J. Magn. Reson. Imaging, 2004, 19, 546-54, DOI: 10.1002/jmri.20039;
123. R. G. Henry, D. B. Vigneron, N. J. Fischbein, P. E. Grant, M. R. Day, S. M. Noworolski, J. M. Star-Lack, L. L. Wald, W. P. Dillon, S. M. Chang and S. J. Nelson, Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas, AJNR Am. J. Neuroradiol., 2000, 21, 357-66.
124. J. Kurhanewicz, M. G. Swanson, S. J. Nelson and D. B. Vigneron, Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer, J. Magn. Reson. Imaging, 2002, 16, 451-63, DOI: 10.1002/jmri.10172;
125. 1H magnetic resonance spectroscopy: a pilot study, Magn. Reson. Imaging, 2004, 22, 697-706, DOI: 10.1016/j.mri.2004.01.037.
126. 19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles, Curr. Top. Dev. Biol., 2005, 70, 57-76, DOI: 10.1016/S0070-2153(05)70003-X.
127. C. A. Presant, W. Wolf, V. Waluch, C. Wiseman, P. Kennedy, D. Blayney and R. R. Brechner, Association of intratumoral pharmacokinetics of fluorouracil with clinical response, Lancet, 1994, 343, 1184-7.
128. 13C magnetic resonance imaging and spectroscopy, Nat. Med., 2007, 13, 1382-7, DOI: 10.1038/nm1650.
129. D. E. Jenkins, S. F. Yu, Y. S. Hornig, T. Purchio and P. R. Contag, In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer, Clin. Exp. Metastasis, 2003, 20, 745-56.
130. S. A. Boppart, B. E. Bouma, C. Pitris, G. J. Tearney, J. F. Southern, M. E. Brezinski and J. G. Fujimoto, Intraoperative assessment of microsurgery with three-dimensional optical coherence tomography, Radiology, 1998, 208, 81-6.
131. E. S. Olson, T. Jiang, T. A. Aguilera, Q. T. Nguyen, L. G. Ellies, M. Scadeng and R. Y. Tsien, Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 4311-6, DOI: 10.1073/pnas.0910283107.
132. F. Zhou, D. Xing, S. Wu and W. R. Chen, Intravital imaging of tumor apoptosis with FRET probes during tumor therapy, Mol. Imaging Biol., 2009, 12, 63-70, DOI: 10.1007/s11307-009-0235-y.
133. J. C. Jung and M. J. Schnitzer, Multiphoton endoscopy, Opt. Lett., 2003, 28, 902-4.
134. G. E. Weller, M. K. Wong, R. A. Modzelewski, E. Lu, A. L. Klibanov, W. R. Wagner and F. S. Villanueva, Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine, Cancer Res., 2005, 65, 533-9.
135. T. J. Ruers, B. Wiering, J. R. van der Sijp, R. M. Roumen, K. P. de Jong, E. F. Comans, J. Pruim, H. M. Dekker, P. F. Krabbe and W. J. Oyen, Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study, J. Nucl. Med., 2009, 50, 1036-41, DOI: 10.2967/jnumed.109.063040.
136. D. A. Pierce and D. L. Preston, Risks from low doses of radiation, Science, 1996, 272, 632-3.
137. M. Atri, New technologies and directed agents for applications of cancer imaging, J. Clin. Oncol., 2006, 24, 3299-308, DOI: 10.1200/JCO.2006.06.6159. (Pubitemid 46622070)
138. P. Therasse, S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A. T. van Oosterom, M. C. Christian and S. G. Gwyther, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J. Natl. Cancer Inst., 2000, 92, 205-16;
139. P. Therasse, E. A. Eisenhauer and J. Verweij, RECIST revisited: a review of validation studies on tumour assessment, Eur. J. Cancer, 2006, 42, 1031-9, DOI: 10.1016/j.ejca.2006.01.026.
140. T. Beyer, D. W. Townsend and T. M. Blodgett, Dual-modality PET/CT tomography for clinical oncology, Q. J. Nucl. Med., 2002, 46, 24-34.
141. D. Lardinois, W. Weder, T. F. Hany, E. M. Kamel, S. Korom, B. Seifert, G. K. von Schulthess and H. C. Steinert, Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography, N. Engl. J. Med., 2003, 348, 2500-7, DOI: 10.1056/NEJMoa022136;
142. B. Fischer, U. Lassen, J. Mortensen, S. Larsen, A. Loft, A. Bertelsen, J. Ravn, P. Clementsen, A. Hogholm, K. Larsen, T. Rasmussen, S. Keiding, A. Dirksen, O. Gerke, B. Skov, I. Steffensen, H. Hansen, P. Vilmann, G. Jacobsen, V. Backer, N. Maltbaek, J. Pedersen, H. Madsen, H. Nielsen and L. Hojgaard, Preoperative staging of lung cancer with combined PET-CT, N. Engl. J. Med., 2009, 361, 32-9, DOI: 10.1056/NEJMoa0900043.
143. R. L. Wahl, H. Jacene, Y. Kasamon and M. A. Lodge, From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors, J. Nucl. Med., 2009, 50(Suppl 1), 122S-50S, DOI: 10.2967/jnumed.108.057307.
144. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group, Eur. J. Cancer, 1999, 35, 1773-82, DOI: 10.1016/S0959-8049(99)00229-4.
145. T. S. Koh, C. H. Thng, S. Hartono, P. S. Lee, S. P. Choo, D. Y. Poon, H. C. Toh and S. Bisdas, Dynamic contrast-enhanced CT imaging of hepatocellular carcinoma in cirrhosis: feasibility of a prolonged dual-phase imaging protocol with tracer kinetics modeling, Eur. Radiol., 2009, 19, 1184-96, DOI: 10.1007/s00330-008-1252-y;
146. S. Bisdas, G. N. Konstantinou, P. S. Lee, C. H. Thng, J. Wagenblast, M. Baghi and T. S. Koh, Dynamic contrast-enhanced CT of head and neck tumors: perfusion measurements using a distributed-parameter tracer kinetic model. Initial results and comparison with deconvolution-based analysis, Phys. Med. Biol., 2007, 52, 6181-96, DOI: 10.1088/0031-9155/52/20/007.
147. M. L. Ah-See, A. Makris, N. J. Taylor, M. Harrison, P. I. Richman, R. J. Burcombe, J. J. Stirling, J. A. d'Arcy, D. J. Collins, M. R. Pittam, D. Ravichandran and A. R. Padhani, Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer, Clin. Cancer Res., 2008, 14, 6580-9, DOI: 10.1158/1078-0432.CCR-07-4310;
148. P. L. Choyke, A. J. Dwyer and M. V. Knopp, Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging, J. Magn. Reson. Imaging, 2003, 17, 509-20, DOI: 10.1002/jmri.10304.
149. H. W. van Laarhoven, W. Fiedler, I. M. Desar, J. J. van Asten, S. Marreaud, D. Lacombe, A. S. Govaerts, J. Bogaerts, P. Lasch, J. N. Timmer-Bonte, A. Lambiase, C. Bordignon, C. J. Punt, A. Heerschap and C. M. van Herpen, Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041), Clin. Cancer Res., 2010, 16, 1315-23, DOI: 10.1158/1078-0432.CCR-09-1621;
150. J. Baar, P. Silverman, J. Lyons, P. Fu, F. Abdul-Karim, N. Ziats, J. Wasman, P. Hartman, J. Jesberger, L. Dumadag, E. Hohler, R. Leeming, R. Shenk, H. Chen, K. McCrae, A. Dowlati, S. C. Remick and B. Overmoyer, A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers, Clin. Cancer Res., 2009, 15, 3583-90, DOI: 10.1158/1078-0432.CCR-08-2917;
151. T. Meyer, A. M. Gaya, G. Dancey, M. R. Stratford, S. Othman, S. K. Sharma, D. Wellsted, N. J. Taylor, J. J. Stirling, L. Poupard, L. K. Folkes, P. S. Chan, R. B. Pedley, K. A. Chester, K. Owen, J. A. Violet, A. Malaroda, A. J. Green, J. Buscombe, A. R. Padhani, G. J. Rustin and R. H. Begent, A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas, Clin. Cancer Res., 2009, 15, 4484-92, DOI: 10.1158/1078-0432.CCR-09-0035;
152. O. M. Hahn, C. Yang, M. Medved, G. Karczmar, E. Kistner, T. Karrison, E. Manchen, M. Mitchell, M. J. Ratain and W. M. Stadler, Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma, J. Clin. Oncol., 2008, 26, 4572-8, DOI: 10.1200/JCO.2007.15.5655;
153. Q. S. Ng, V. Goh, J. Milner, M. R. Stratford, L. K. Folkes, G. M. Tozer, M. I. Saunders and P. J. Hoskin, Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study, Lancet Oncol., 2007, 8, 111-8, DOI: 10.1016/S1470-2045(07)70001-3;
154. Q. S. Ng, V. Goh, D. Carnell, K. Meer, A. R. Padhani, M. I. Saunders and P. J. Hoskin, Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer, Int. J. Radiat. Oncol., Biol., Phys., 2007, 67, 1375-80, DOI: 10.1016/j.ijrobp.2006.11.028.
155. D. A. Hamstra, C. J. Galban, C. R. Meyer, T. D. Johnson, P. C. Sundgren, C. Tsien, T. S. Lawrence, L. Junck, D. J. Ross, A. Rehemtulla, B. D. Ross and T. L. Chenevert, Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival, J. Clin. Oncol., 2008, 26, 3387-94, DOI: 10.1200/JCO.2007.15.2363;
156. S. Kim, L. Loevner, H. Quon, E. Sherman, G. Weinstein, A. Kilger and H. Poptani, Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck, Clin. Cancer Res., 2009, 15, 986-94, DOI: 10.1158/1078-0432.CCR-08-1287;
157. Y. Cui, X. P. Zhang, Y. S. Sun, L. Tang and L. Shen, Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases, Radiology, 2008, 248, 894-900, DOI: 10.1148/radiol.2483071407;
158. W. Reichardt, E. Juettner, M. Uhl, D. V. Elverfeldt and U. Kontny, Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma, Invest. Radiol., 2009, 44, 298-303, DOI: 10.1097/RLI. 0b013e31819dcc84.
159. A. R. Padhani and K. A. Miles, Multiparametric imaging of tumor response to therapy, Radiology, 2010, 256, 348-64, DOI: 10.1148/radiol.10091760.
160. H. Ashamalla, S. Rafla, K. Parikh, B. Mokhtar, G. Goswami, S. Kambam, H. Abdel-Dayem, A. Guirguis, P. Ross and A. Evola, The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer, Int. J. Radiat. Oncol., Biol., Phys., 2005, 63, 1016-23, DOI: 10.1016/j.ijrobp.2005.04.021.
161. E. Topkan, A. A. Yavuz, M. Aydin, C. Onal, F. Yapar and M. N. Yavuz, Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma, J. Exp. Clin. Cancer Res., 2008, 27, 41, DOI: 10.1186/1756-9966-27-41.
162. S. Tatli, V. H. Gerbaudo, M. Mamede, K. Tuncali, P. B. Shyn and S. G. Silverman, Abdominal masses sampled at PET/CT-guided percutaneous biopsy: initial experience with registration of prior PET/CT images, Radiology, 2010, 256, 305-11, DOI: 10.1148/radiol.10090931.
163. E. J. Somer, P. K. Marsden, N. A. Benatar, J. Goodey, M. J. O'Doherty and M. A. Smith, PET-MR image fusion in soft tissue sarcoma: accuracy, reliability and practicality of interactive point-based and automated mutual information techniques, Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 54-62.
164. E. S. Olson, T. Jiang, T. A. Aguilera, Q. T. Nguyen, L. G. Ellies, M. Scadeng and R. Y. Tsien, Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 4311-6, DOI: 10.1073/pnas.0910283107.
165. M. Nahrendorf, E. Keliher, B. Marinelli, P. Waterman, P. F. Feruglio, L. Fexon, M. Pivovarov, F. K. Swirski, M. J. Pittet, C. Vinegoni and R. Weissleder, Hybrid PET-optical imaging using targeted probes, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 7910-5, DOI: 10.1073/pnas.0915163107.
166. M. Nahrendorf, H. Zhang, S. Hembrador, P. Panizzi, D. E. Sosnovik, E. Aikawa, P. Libby, F. K. Swirski and R. Weissleder, Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis, Circulation, 2008, 117, 379-87, DOI: 10.1161/CIRCULATIONAHA.107.741181.
167. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich and W. L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 1987, 235, 177-82.
168. E. E. Lower, E. Glass, R. Blau and S. Harman, HER-2/neu expression in primary and metastatic breast cancer, Breast Cancer Res. Treat., 2009, 113, 301-6, DOI: 10.1007/s10549-008-9931-6.
169. M. Brunelli, E. Manfrin, G. Martignoni, K. Miller, A. Remo, D. Reghellin, S. Bersani, S. Gobbo, A. Eccher, M. Chilosi and F. Bonetti, Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria, Am. J. Clin. Pathol., 2009, 131, 678-82, DOI: 10.1309/AJCP09VUTZWZXBMJ.
170. Y. Tang, J. Wang, D. A. Scollard, H. Mondal, C. Holloway, H. J. Kahn and R. M. Reilly, Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments, Nucl. Med. Biol., 2005, 32, 51-8, DOI: 10.1016/j.nucmedbio.2004.08.003.
171. T. A. Smith, Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging, Br. J. Radiol., 2010, 83, 638-44, DOI: 10.1259/bjr/31053812.
172. A. Orlova, V. Tolmachev, R. Pehrson, M. Lindborg, T. Tran, M. Sandstrom, F. Y. Nilsson, A. Wennborg, L. Abrahmsen and J. Feldwisch, Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors, Cancer Res., 2007, 67, 2178-86, DOI: 10.1158/0008-5472.CAN-06-2887. (Pubitemid 46424237)
173. 68Ga-labeled affibody molecules, J. Nucl. Med., 2010, 51, 892-7, DOI: 10.2967/jnumed.109. 073239.
174. A. C. Wolff, M. E. Hammond, J. N. Schwartz, K. L. Hagerty, D. C. Allred, R. J. Cote, M. Dowsett, P. L. Fitzgibbons, W. M. Hanna, A. Langer, L. M. McShane, S. Paik, M. D. Pegram, E. A. Perez, M. F. Press, A. Rhodes, C. Sturgeon, S. E. Taube, R. Tubbs, G. H. Vance, M. van de Vijver, T. M. Wheeler and D. F. Hayes, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J. Clin. Oncol., 2007, 25, 118-45, DOI: 10.1200/JCO.2006.09.2775. (Pubitemid 350003059)
175. P. Workman, Pharmacokinetics and cancer: successes, failures and future prospects, Cancer Surv., 1993, 17, 1-26;
176. B. M. Seddon and P. Workman, The role of functional and molecular imaging in cancer drug discovery and development, Br. J. Radiol., 2003, 76(Spec. No. 2), S128-38.
177. D. M. Potter, Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer, Stat. Med., 2002, 21, 1805-23, DOI: 10.1002/sim.1141.
178. M. J. Ratain, R. L. Schilsky, B. A. Conley and M. J. Egorin, Pharmacodynamics in cancer therapy, J. Clin. Oncol., 1990, 8, 1739-53.
179. A. J. Fischman, N. M. Alpert and R. H. Rubin, Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action, Clin. Pharmacokinet., 2002, 41, 581-602, DOI: 10.2165/00003088-200241080-00003. (Pubitemid 34848364)
180. 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging, J. Nucl. Med., 2009, 50, 2073-81, DOI: 10.2967/jnumed.109.063503;
181. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody, Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 850-8, DOI: 10.1007/s00259-006-0361-6.
182. G. Niu, Z. Li, Q. Cao and X. Chen, Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab, Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 1510-9, DOI: 10.1007/s00259-009-1158-1.
183. I. R. Wilding and J. A. Bell, Improved early clinical development through human microdosing studies, Drug Discovery Today, 2005, 10, 890-4, DOI: 10.1016/S1359-6446(05)03509-9.
184. T. H. Oude Munnink, M. A. Korte, W. B. Nagengast, H. Timmer-Bosscha, C. P. Schroder, J. R. Jong, G. A. Dongen, M. R. Jensen, C. Quadt, M. N. Hooge and E. G. Vries, (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft, Eur. J. Cancer, 2010, 46, 678-84, DOI: 10.1016/j.ejca.2009.12.009.
185. A. Citri, I. Alroy, S. Lavi, C. Rubin, W. Xu, N. Grammatikakis, C. Patterson, L. Neckers, D. W. Fry and Y. Yarden, Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy, EMBO J., 2002, 21, 2407-17, DOI: 10.1093/emboj/21.10.2407. (Pubitemid 34546713)
186. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer, Clin. Pharmacol. Ther., 2010, 87, 586-92, DOI: 10.1038/clpt.2010.12.
187. R. Katz, Biomarkers and surrogate markers: an FDA perspective, NeuroRx, 2004, 1, 189-95. (Pubitemid 46604746)
188. M. M. Gottesman, How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture, Cancer Res., 1993, 53, 747-54;
189. S. W. Lowe, H. E. Ruley, T. Jacks and D. E. Housman, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell, 1993, 74, 957-67, DOI: 10.1016/0092-8674(93)90719-7.
190. S. Kraljevic, M. Sedic, M. Scott, P. Gehrig, R. Schlapbach and K. Pavelic, Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view?, Cancer Treat. Rev., 2006, 32, 619-29, DOI: 10.1016/j.ctrv.2006.09.002. (Pubitemid 44752563)
191. A. Trumpp and O. D. Wiestler, Mechanisms of Disease: cancer stem cells[mdash]targeting the evil twin, Nat. Clin. Pract. Oncol., 2008, 5, 337-347;
192. R. M. Glasspool, J. M. Teodoridis and R. Brown, Epigenetics as a mechanism driving polygenic clinical drug resistance, Br. J. Cancer, 2006, 94, 1087-1092.
193. L. A. Carey, E. C. Dees, L. Sawyer, L. Gatti, D. T. Moore, F. Collichio, D. W. Ollila, C. I. Sartor, M. L. Graham and C. M. Perou, The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes, Clin. Cancer Res., 2007, 13, 2329-34, DOI: 10.1158/1078-0432.CCR-06-1109; (Pubitemid 46698581)
194. V. C. Hodgkinson, G. L. Eagle, P. J. Drew, M. J. Lind and L. Cawkwell, Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status, Cancer Lett., 2010, 294, 13-24, DOI: 10.1016/j.canlet.2010.01. 036.
195. P. Kannan, C. John, S. S. Zoghbi, C. Halldin, M. M. Gottesman, R. B. Innis and M. D. Hall, Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications, Clin. Pharmacol. Ther., 2009, 86, 368-77, DOI: 10.1038/clpt.2009.138.
196. M. Fellner, W. Dillenburg, H. G. Buchholz, N. Bausbacher, M. Schreckenberger, F. Renz, F. Rosch and O. Thews, Assessing p-Glycoprotein (Pgp) Activity in vivo Utilizing (68)Ga-Schiff Base Complexes, Mol. Imaging Biol., 2010, DOI: 10.1007/s11307-010-0410-1;
197. 99mTc]tetrofosmin, Cancer Biother. Radiopharm., 2009, 24, 215-27, DOI: 10.1089/cbr.2008.0539;
198. N. H. Hendrikse and W. Vaalburg, Imaging of P glycoprotein function in vivo with PET, Novartis Found. Symp., 2002, 243, 137-45, DOI: 10.1002/0470846356.ch10; discussion 145-8, 180-5.
199. S. V. Sharma, D. Y. Lee, B. Li, M. P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M. A. Fischbach, K.-K. Wong, K. Brandstetter, B. Wittner, S. Ramaswamy, M. Classon and J. Settleman, A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations, Cell, 2010, 141, 69-80.
200. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau and E. Van Cutsem, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N. Engl. J. Med., 2004, 351, 337-45, DOI: 10.1056/NEJMoa033025. (Pubitemid 38944402)
201. J. Souglakos, A. Kalykaki, L. Vamvakas, N. Androulakis, K. Kalbakis, S. Agelaki, N. Vardakis, M. Tzardi, A. P. Kotsakis, J. Gioulbasanis, D. Tsetis, G. Sfakiotaki, D. Chatzidaki, D. Mavroudis and V. Georgoulias, Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy, Ann. Oncol., 2007, 18, 305-10, DOI: 10.1093/annonc/mdl392. (Pubitemid 46323098)
202. E. Pasquier, M. Kavallaris and N. Andre, Metronomic chemotherapy: new rationale for new directions, Nat. Rev. Clin. Oncol., 2010, 7, 455-65, DOI: 10.1038/nrclinonc.2010.82;
203. R. S. Kerbel and B. A. Kamen, The anti-angiogenic basis of metronomic chemotherapy, Nat. Rev. Cancer, 2004, 4, 423-36, DOI: 10.1038/nrc1369.
204. G. Gasparini, Metronomic scheduling: the future of chemotherapy?, Lancet Oncol., 2001, 2, 733-40, DOI: 10.1016/S1470-2045(01)00587-3. (Pubitemid 33134058)
205. R. Lord, S. Nair, A. Schache, J. Spicer, N. Somaihah, V. Khoo and H. Pandha, Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study, J. Urol., 2007, 177, 2136-40, DOI: 10.1016/j.juro.2007.01.143; discussion 2140. (Pubitemid 46726410)
206. J. M. Jurado, A. Sanchez, B. Pajares, E. Perez, L. Alonso and E. Alba, Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer, Clin. Transl. Oncol., 2008, 10, 583-6, DOI: 10.1007/s12094-008-0254-7.
207. M. Colleoni, A. Rocca, M. T. Sandri, L. Zorzino, G. Masci, F. Nole, G. Peruzzotti, C. Robertson, L. Orlando, S. Cinieri, B. F. de, G. Viale and A. Goldhirsch, Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels, Ann. Oncol., 2002, 13, 73-80;
208. S. Dellapasqua, F. Bertolini, V. Bagnardi, E. Campagnoli, E. Scarano, R. Torrisi, Y. Shaked, P. Mancuso, A. Goldhirsch, A. Rocca, E. Pietri and M. Colleoni, Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer, J. Clin. Oncol., 2008, 26, 4899-905, DOI: 10.1200/JCO.2008.17.4789.
209. S. F. Rosebrough, Two-step immunological approaches for imaging and therapy, Q. J. Nucl. Med., 1996, 40, 234-51.
210. C. Bremer, S. Bredow, U. Mahmood, R. Weissleder and C. H. Tung, Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model, Radiology, 2001, 221, 523-9.
211. G. Lucignani and M. Rodriguez-Porcel, In vivo imaging for stem cell therapy: new developments and future challenges, Eur. J. Nucl.Med. Mol. Imaging, 2011, 38, 400-5, DOI: 10.1007/s00259-010-1695-7;
212. M. Rodriguez-Porcel, In vivo imaging and monitoring of transplanted stem cells: clinical applications, Curr. Cardiol. Rep., 2010, 12, 51-8, DOI: 10.1007/s11886-009-0073-1;
213. R. Schafer, R. Bantleon, R. Kehlbach, G. Siegel, J. Wiskirchen, H. Wolburg, T. Kluba, F. Eibofner, H. Northoff, C. D. Claussen and H. P. Schlemmer, Functional investigations on human mesenchymal stem cells exposed to magnetic fields and labeled with clinically approved iron nanoparticles, BMC Cell Biol., 2010, 11, 22, DOI: 10.1186/1471-2121-11-22;
214. T. Higuchi, M. Anton, A. Saraste, K. Dumler, J. Pelisek, S. G. Nekolla, F. M. Bengel and M. Schwaiger, Reporter gene PET for monitoring survival of transplanted endothelial progenitor cells in the rat heart after pretreatment with VEGF and atorvastatin, J. Nucl. Med., 2009, 50, 1881-6, DOI: 10.2967/jnumed.109.067801.
215. M. A. Rueger, H. Backes, M. Walberer, B. Neumaier, R. Ullrich, M. L. Simard, B. Emig, G. R. Fink, M. Hoehn, R. Graf and M. Schroeter, Noninvasive imaging of endogenous neural stem cell mobilization in vivo using positron emission tomography, J. Neurosci., 2010, 30, 6454-60, DOI: 10.1523/JNEUROSCI. 6092-09.2010.
216. J. K. Willmann, R. Paulmurugan, M. Rodriguez-Porcel, W. Stein, T. J. Brinton, A. J. Connolly, C. H. Nielsen, A. M. Lutz, J. Lyons, F. Ikeno, Y. Suzuki, J. Rosenberg, I. Y. Chen, J. C. Wu, A. C. Yeung, P. Yock, R. C. Robbins and S. S. Gambhir, Imaging gene expression in human mesenchymal stem cells: from small to large animals, Radiology, 2009, 252, 117-27, DOI: 10.1148/radiol. 2513081616.
217. I. Penuelas, G. Mazzolini, J. F. Boan, B. Sangro, J. Marti-Climent, M. Ruiz, J. Ruiz, N. Satyamurthy, C. Qian, J. R. Barrio, M. E. Phelps, J. A. Richter, S. S. Gambhir and J. Prieto, Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients, Gastroenterology, 2005, 128, 1787-95, DOI: 10.1053/j.gastro.2005.03.024. (Pubitemid 40824689)
218. S. S. Yaghoubi, M. C. Jensen, N. Satyamurthy, S. Budhiraja, D. Paik, J. Czernin and S. S. Gambhir, Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma, Nat. Clin. Pract. Oncol., 2009, 6, 53-8, DOI: 10.1038/ncponc1278.
219. C. Tsurumi, N. Esser, E. Firat, S. Gaedicke, M. Follo, M. Behe, U. Elsasser-Beile, A. L. Grosu, R. Graeser and G. Niedermann, Non-invasive in vivo imaging of tumor-associated CD133/prominin, PLoS One, 2010, 5, e15605, DOI: 10.1371/journal.pone.0015605.
220. A. Weigmann, D. Corbeil, A. Hellwig and W. B. Huttner, Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells, Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 12425-30;
221. K. Kemper, M. R. Sprick, M. de Bree, A. Scopelliti, L. Vermeulen, M. Hoek, J. Zeilstra, S. T. Pals, H. Mehmet, G. Stassi and J. P. Medema, The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation, Cancer Res., 2010, 70, 719-29, DOI: 10.1158/0008-5472.CAN-09- 1820;
222. S. K. Singh, I. D. Clarke, M. Terasaki, V. E. Bonn, C. Hawkins, J. Squire and P. B. Dirks, Identification of a cancer stem cell in human brain tumors, Cancer Res., 2003, 63, 5821-8;
223. G. Ferrandina, M. Petrillo, G. Bonanno and G. Scambia, Targeting CD133 antigen in cancer, Expert Opin. Ther. Targets, 2009, 13, 823-37, DOI: 10.1517/14728220903005616.
224. A. Pal, A. Glekas, M. Doubrovin, J. Balatoni, M. Namavari, T. Beresten, D. Maxwell, S. Soghomonyan, A. Shavrin, L. Ageyeva, R. Finn, S. M. Larson, W. Bornmann and J. G. Gelovani, Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography, Mol. Imaging Biol., 2006, 8, 262-77, DOI: 10.1007/s11307-006-0049-0. (Pubitemid 44446020)
225. J. M. Perez, L. Josephson and R. Weissleder, Use of magnetic nanoparticles as nanosensors to probe for molecular interactions, ChemBioChem, 2004, 5, 261-4, DOI: 10.1002/cbic.200300730. (Pubitemid 39257117)
226. H. K. Sajja, M. P. East, H. Mao, Y. A. Wang, S. Nie and L. Yang, Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect, Curr. Drug Discovery Technol., 2009, 6, 43-51.
227. C. G. Hadjipanayis, R. Machaidze, M. Kaluzova, L. Wang, A. J. Schuette, H. Chen, X. Wu and H. Mao, EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma, Cancer Res., 2010, 70, 6303-12, DOI: 10.1158/0008-5472.CAN-10-1022.
228. E. A. O'Flynn, A. R. Wilson and M. J. Michell, Image-guided breast biopsy: state-of-the-art, Clin. Radiol., 2010, 65, 259-70, DOI: 10.1016/j.crad.2010.01.008.
229. C. E. Mountford, R. L. Somorjai, P. Malycha, L. Gluch, C. Lean, P. Russell, B. Barraclough, D. Gillett, U. Himmelreich, B. Dolenko, A. E. Nikulin and I. C. Smith, Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy, Br. J. Surg., 2001, 88, 1234-40, DOI: 10.1046/j.0007-1323.2001.01864.x. (Pubitemid 34015609)
230. C. Mountford, S. Ramadan, P. Stanwell and P. Malycha, Proton MRS of the breast in the clinical setting, NMR Biomed., 2009, 22, 54-64, DOI: 10.1002/nbm.1301.
231. B. Turkbey, P. A. Pinto and P. L. Choyke, Imaging techniques for prostate cancer: implications for focal therapy, Nat. Rev. Urol., 2009, 6, 191-203, DOI: 10.1038/nrurol.2009.27.
232. D. L. Langer, T. H. van der Kwast, A. J. Evans, J. Trachtenberg, B. C. Wilson and M. A. Haider, Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI, J. Magn. Reson. Imaging, 2009, 30, 327-34, DOI: 10.1002/jmri.21824.
233. R. C. Susil, C. Menard, A. Krieger, J. A. Coleman, K. Camphausen, P. Choyke, G. Fichtinger, L. L. Whitcomb, C. N. Coleman and E. Atalar, Transrectal prostate biopsy and fiducial marker placement in a standard 1.5 T magnetic resonance imaging scanner, J. Urol., 2006, 175, 113-20, DOI: 10.1016/S0022-5347(05)00065-0; (Pubitemid 41797106)
234. A. V. D'Amico, C. M. Tempany, R. Cormack, N. Hata, M. Jinzaki, K. Tuncali, M. Weinstein and J. P. Richie, Transperineal magnetic resonance image guided prostate biopsy, J. Urol., 2000, 164, 385-7, DOI: 10.1016/S0022-5347(05) 67366-1.
235. A. K. Singh, J. Kruecker, S. Xu, N. Glossop, P. Guion, K. Ullman, P. L. Choyke and B. J. Wood, Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy, BJU Int., 2008, 101, 841-5, DOI: 10.1111/j.1464-410X.2007.07348.x;
236. B. Turkbey, S. Xu, J. Kruecker, J. Locklin, Y. Pang, M. Bernardo, M. J. Merino, B. J. Wood, P. L. Choyke and P. A. Pinto, Documenting the location of prostate biopsies with image fusion, BJU Int., 2011, 107, 53, DOI: 10.1111/j.1464-410X.2010.09483.x.
237. S. Xu, J. Kruecker, B. Turkbey, N. Glossop, A. K. Singh, P. Choyke, P. Pinto and B. J. Wood, Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies, Comput.-Aided Surg., 2008, 13, 255-64, DOI: 10.3109/10929080802364645.
238. B. Klaeser, J. Wiskirchen, J. Wartenberg, T. Weitzel, R. A. Schmid, M. D. Mueller and T. Krause, PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact, Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 2027, DOI: 10.1007/s00259-010-1524-z.
239. P. R. B. Mark I. Rowley, Anthony Coolen and Borivoj Vojnovic, in BIOS, SPIE Photonics West, The Moscone Center, San Francisco, California, USA, 2011, pp. 7903-74.
240. M. Offterdinger and P. I. Bastiaens, Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane, Traffic, 2008, 9, 147-55.
241. R. E. Itoh, K. Kurokawa, A. Fujioka, A. Sharma, B. J. Mayer and M. Matsuda, A FRET-based probe for epidermal growth factor receptor bound non-covalently to a pair of synthetic amphipathic helixes, Exp. Cell Res., 2005, 307, 142-52, DOI: 10.1016/j.yexcr.2005.02.026. (Pubitemid 40732740)
242. A. Y. Ting, K. H. Kain, R. L. Klemke and R. Y. Tsien, Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells, Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 15003-8, DOI: 10.1073/pnas.211564598;
243. J. Zhang, R. E. Campbell, A. Y. Ting and R. Y. Tsien, Creating new
244. R. B. Sekar and A. Periasamy, Fluorescence resonance energy transfer (FRET) microscopy imaging of live cell protein localizations, J. Cell Biol., 2003, 160, 629-33, DOI: 10.1083/jcb.200210140; (Pubitemid 36298259)
245. M. Peter, S. M. Ameer-Beg, M. K. Hughes, M. D. Keppler, S. Prag, M. Marsh, B. Vojnovic and T. Ng, Multiphoton-FLIM quantification of the EGFP-mRFP1 FRET pair for localization of membrane receptor-kinase interactions, Biophys. J., 2005, 88, 1224-37, DOI: 10.1529/biophysj.104.050153; (Pubitemid 40975950)
246. J. R. Morris, C. Boutell, M. Keppler, R. Densham, D. Weekes, A. Alamshah, L. Butler, Y. Galanty, L. Pangon, T. Kiuchi, T. Ng and E. Solomon, The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress, Nature, 2009, 462, 886-90, DOI: 10.1038/nature08593;
247. A. Kong, V. Calleja, P. Leboucher, A. Harris, P. J. Parker and B. Larijani, HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells, PLoS One, 2008, 3, e2881, DOI: 10.1371/journal.pone.0002881;
248. G. Fruhwirth, D. R. Matthews, A. Brock, M. Keppler, B. Vojnovic, T. Ng, S. M. Ameer-Beg, presented in part at SPIE BIOS/Photonics West 2009, Yea.
249. M. Peter and S. M. Ameer-Beg, Imaging molecular interactions by multiphoton FLIM, Biol. Cell, 2004, 96, 231-6, DOI: 10.1016/j.biolcel.2003.12. 006; (Pubitemid 38461447)
250. T. Forster, in Modern Quantum Chemistry, ed. Sinanoglu, Academic Press, New York, 1965, vol. III, pp. 93-137.
251. G. O. Fruhwirth, S. Ameer-Beg, R. Cook, T. Watson, T. Ng and F. Festy, Fluorescence lifetime endoscopy using TCSPC for the measurement of FRET in live cells, Opt. Express, 2010, 18, 11148-58, DOI: 10.1364/OE.18.011148.
252. S. Urbe, J. McCullough, P. Row, I. A. Prior, R. Welchman and M. J. Clague, Control of growth factor receptor dynamics by reversible ubiquitination, Biochem. Soc. Trans., 2006, 34, 754-6, DOI: 10.1042/BST0340754.
253. M. J. Clague and S. Urbe, Multivesicular bodies, Curr. Biol., 2008, 18, R402-4, DOI: 10.1016/j.cub.2008.02.068.
254. B. Schoeberl, E. A. Pace, J. B. Fitzgerald, B. D. Harms, L. Xu, L. Nie, B. Linggi, A. Kalra, V. Paragas, R. Bukhalid, V. Grantcharova, N. Kohli, K. A. West, M. Leszczyniecka, M. J. Feldhaus, A. J. Kudla and U. B. Nielsen, Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis, Sci. Signaling, 2009, 2, ra31, DOI: 10.1126/scisignal.2000352.
255. A. Guo, J. Villen, J. Kornhauser, K. A. Lee, M. P. Stokes, K. Rikova, A. Possemato, J. Nardone, G. Innocenti, R. Wetzel, Y. Wang, J. MacNeill, J. Mitchell, S. P. Gygi, J. Rush, R. D. Polakiewicz and M. J. Comb, Signaling networks assembled by oncogenic EGFR and c-Met, Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 692-7, DOI: 10.1073/pnas.0707270105.
256. J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C. M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley and P. A. Janne, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 2007, 316, 1039-43, DOI: 10.1126/science.1141478.
257. M. P. Gordon, T. Ha and P. R. Selvin, Single-molecule high-resolution imaging with photobleaching, Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 6462-5, DOI: 10.1073/pnas.0401638101.
258. E. Toprak and P. R. Selvin, New fluorescent tools for watching nanometer-scale conformational changes of single molecules, Annu. Rev. Biophys. Biomol. Struct., 2007, 36, 349-69, DOI: 10.1146/annurev.biophys.36.040306. 132700;
259. L. S. Churchman, Z. Okten, R. S. Rock, J. F. Dawson and J. A. Spudich, Single molecule high-resolution colocalization of Cy3 and Cy5 attached to macromolecules measures intramolecular distances through time, Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 1419-23, DOI: 10.1073/pnas.0409487102.
260. Y. Mosesson, G. B. Mills and Y. Yarden, Derailed endocytosis: an emerging feature of cancer, Nat. Rev. Cancer, 2008, 8, 835-50;
261. K. Shtiegman, B. S. Kochupurakkal, Y. Zwang, G. Pines, A. Starr, A. Vexler, A. Citri, M. Katz, S. Lavi, Y. Ben-Basat, S. Benjamin, S. Corso, J. Gan, R. B. Yosef, S. Giordano and Y. Yarden, Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling, Oncogene, 2007, 26, 6968-6978. (Pubitemid 350014608)
262. O. Zach and D. Lutz, Tumor cell detection in peripheral blood and bone marrow, Curr. Opin. Oncol., 2006, 18, 48-56, DOI: 10.1097/01.cco.0000198973. 51615.fa. (Pubitemid 43740450)
263. K. Pantel, R. H. Brakenhoff and B. Brandt, Detection, clinical relevance and specific biological properties of disseminating tumour cells, Nat. Rev. Cancer, 2008, 8, 329-40, DOI: 10.1038/nrc2375.
264. S. Braun, F. D. Vogl, B. Naume, W. Janni, M. P. Osborne, R. C. Coombes, G. Schlimok, I. J. Diel, B. Gerber, G. Gebauer, J. Y. Pierga, C. Marth, D. Oruzio, G. Wiedswang, E. F. Solomayer, G. Kundt, B. Strobl, T. Fehm, G. Y. Wong, J. Bliss, A. Vincent-Salomon and K. Pantel, A pooled analysis of bone marrow micrometastasis in breast cancer, N. Engl. J. Med., 2005, 353, 793-802, DOI: 10.1056/NEJMoa050434. (Pubitemid 41215488)
265. S. Nagrath, L. V. Sequist, S. Maheswaran, D. W. Bell, D. Irimia, L. Ulkus, M. R. Smith, E. L. Kwak, S. Digumarthy, A. Muzikansky, P. Ryan, U. J. Balis, R. G. Tompkins, D. A. Haber and M. Toner, Isolation of rare circulating tumour cells in cancer patients by microchip technology, Nature, 2007, 450, 1235-9, DOI: 10.1038/nature06385.
266. G. T. Budd, M. Cristofanilli, M. J. Ellis, A. Stopeck, E. Borden, M. C. Miller, J. Matera, M. Repollet, G. V. Doyle, L. W. Terstappen and D. F. Hayes, Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer, Clin. Cancer Res., 2006, 12, 6403-9, DOI: 10.1158/1078-0432.CCR- 05-1769. (Pubitemid 44799711)
267. M. Balic, H. Lin, L. Young, D. Hawes, A. Giuliano, G. McNamara, R. H. Datar and R. J. Cote, Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype, Clin. Cancer Res., 2006, 12, 5615-21, DOI: 10.1158/1078-0432.CCR-06- 0169. (Pubitemid 44629587)
268. K. Pantel, C. Alix-Panabieres and S. Riethdorf, Cancer micrometastases, Nat. Rev. Clin. Oncol., 2009, 6, 339-51, DOI: 10.1038/nrclinonc.2009.44.
269. J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B.Mlecnik, C. Lagorce-Pages, M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoue, P. Bruneval, P. H. Cugnenc, Z. Trajanoski, W. H. Fridman and F. Pages, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 2006, 313, 1960-4, DOI: 10.1126/science.1129139.
270. A. Hemsen, L. Riethdorf, N. Brunner, J. Berger, S. Ebel, C. Thomssen, F. Janicke and K. Pantel, Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells, Int. J. Cancer, 2003, 107, 903-9, DOI: 10.1002/ijc.11488; (Pubitemid 37429831)
271. N. Reimers, K. Zafrakas, V. Assmann, C. Egen, L. Riethdorf, S. Riethdorf, J. Berger, S. Ebel, F. Janicke, G. Sauter and K. Pantel, Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells, Clin. Cancer Res., 2004, 10, 3422-8, DOI: 10.1158/1078-0432.CCR-03-0610. (Pubitemid 38685448)
272. N. L. Komarova and D. Wodarz, Drug resistance in cancer: principles of emergence and prevention, Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 9714-9, DOI: 10.1073/pnas.0501870102. (Pubitemid 40981746)
273. C. L. Sawyers, Calculated resistance in cancer, Nat. Med., 2005, 11, 824-5, DOI: 10.1038/nm0805-824.
274. A. M. Xu and P. H. Huang, Receptor tyrosine kinase coactivation networks in cancer, Cancer Res., 2010, 70, 3857-60, DOI: 10.1158/0008-5472.CAN-10-0163.
275. X. Huang, L. Gao, S. Wang, J. L. McManaman, A. D. Thor, X. Yang, F. J. Esteva and B. Liu, Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin, Cancer Res., 2010, 70, 1204-14, DOI: 10.1158/0008-5472.CAN-09-3321.
276. J. M. Stommel, A. C. Kimmelman, H. Ying, R. Nabioullin, A. H. Ponugoti, R. Wiedemeyer, A. H. Stegh, J. E. Bradner, K. L. Ligon, C. Brennan, L. Chin and R. A. DePinho, Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies, Science, 2007, 318, 287-90, DOI: 10.1126/science.1142946.
277. G. Fruhwirth, L. Fernandez, G. Weitsman, G. S. Patel, M. T. Kelleher, A. Brock, S. Poland, D. R. Matthews, G. Keri, P. R. Barber, B. Vojnovic, S. M. Ameer-Beg, K. Lawler, A. Coolen, F. Fraternali and T. Ng, The use of Förster resonance energy transfer (FRET) to understand human proteome function: from studying networks to intravital imaging of cancer metastasis. ChemPhysChem, ChemPhysChem, 2011, 12, 442-461, DOI: 10.1002/cphc.201000866.
278. T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C. M. Perou, P. E. Lonning, P. O. Brown, A. L. Borresen-Dale and D. Botstein, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 8418-23, DOI: 10.1073/pnas.0932692100; (Pubitemid 36842560)
279. J. S. Parker, M. Mullins, M. C. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, X. He, Z. Hu, J. F. Quackenbush, I. J. Stijleman, J. Palazzo, J. S. Marron, A. B. Nobel, E. Mardis, T. O. Nielsen, M. J. Ellis, C. M. Perou and P. S. Bernard, Supervised risk predictor of breast cancer based on intrinsic subtypes, J. Clin. Oncol., 2009, 27, 1160-7, DOI: 10.1200/JCO.2008.18. 1370;
280. Z. Hu, C. Fan, D. S. Oh, J. S. Marron, X. He, B. F. Qaqish, C. Livasy, L. A. Carey, E. Reynolds, L. Dressler, A. Nobel, J. Parker, M. G. Ewend, L. R. Sawyer, J. Wu, Y. Liu, R. Nanda, M. Tretiakova, A. Ruiz Orrico, D. Dreher, J. P. Palazzo, L. Perreard, E. Nelson, M. Mone, H. Hansen, M. Mullins, J. F. Quackenbush, M. J. Ellis, O. I. Olopade, P. S. Bernard and C. M. Perou, The molecular portraits of breast tumors are conserved across microarray platforms, BMC Genomics, 2006, 7, 96, DOI: 10.1186/1471-2164-7-96.
281. L. J. van't Veer, H.Dai, M. J. van de Vijver, Y. D. He, A. A.Hart, M. Mao, H. L. Peterse, K. van der Kooy, M. J. Marton, A. T. Witteveen, G. J. Schreiber, R. M. Kerkhoven, C. Roberts, P. S. Linsley, R. Bernards and S. H. Friend, Gene expression profiling predicts clinical outcome of breast cancer, Nature, 2002, 415, 530-6, DOI: 10.1038/415530a.
282. M. Buyse, S. Loi, L. van't Veer, G. Viale, M. Delorenzi, A. M. Glas, M. S. d'Assignies, J. Bergh, R. Lidereau, P. Ellis, A. Harris, J. Bogaerts, P. Therasse, A. Floore, M. Amakrane, F. Piette, E. Rutgers, C. Sotiriou, F. Cardoso and M. J. Piccart, Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer, J. Natl. Cancer Inst., 2006, 98, 1183-92, DOI: 10.1093/jnci/djj329.
283. H. Y. Chuang, E. Lee, Y. T. Liu, D. Lee and T. Ideker, Network-based classification of breast cancer metastasis, Mol. Syst. Biol., 2007, 3, 140, DOI: 10.1038/msb4100180.
284. A. M. Rutman and M. D. Kuo, Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging, Eur. J. Radiol., 2009, 70, 232-41, DOI: 10.1016/j.ejrad.2009.01.050.
285. E. Segal, C. B. Sirlin, C. Ooi, A. S. Adler, J. Gollub, X. Chen, B. K. Chan, G. R. Matcuk, C. T. Barry, H. Y. Chang and M. D. Kuo, Decoding global gene expression programs in liver cancer by noninvasive imaging, Nat. Biotechnol., 2007, 25, 675-80, DOI: 10.1038/nbt1306. (Pubitemid 46897204)
286. M. Diehn, C. Nardini, D. S. Wang, S. McGovern, M. Jayaraman, Y. Liang, K. Aldape, S. Cha and M. D. Kuo, Identification of noninvasive imaging surrogates for brain tumor gene-expression modules, Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 5213-8, DOI: 10.1073/pnas.0801279105.